---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000006"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:24:21.315258+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO

## Summary
- Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.
- CB-010 ANTLER and CB-011 CaMMouflage Phase 1 data expected H1 2025; CB-010 pivotal Phase 3 planned H2 2025 pending HLA matching.
- CB-012 AMpLify Phase 1 in r/r AML: dose level 3 completed with no DLTs; enrolling dose level 4.
- Sri Ryali appointed CFO; $281M cash expected to fund operations into H2 2026.
- CB-012 granted FDA Fast Track and Orphan Drug designation for r/r AML.

## SEC filing metadata
- accession: 0001619856-25-000006
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/0001619856-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/crbu-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000006
- JSON: https://secwatch.observer/filing/0001619856-25-000006.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.